Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Swiss Pilot Screening Study for Unruptured Intracranial Aneurysms to Prevent Subarachnoid Hemorrhage in Smokers

tiistai 10. marraskuuta 2026 päivittänyt: Insel Gruppe AG, University Hospital Bern

Unruptured intracranial aneurysms (UIAs) are potentially life-threatening vascular lesions that may rupture and cause aneurysmal subarachnoid hemorrhage (SAH), a condition associated with substantial morbidity and mortality. The prevalence of UIAs in the general population is approximately 3.2%. Current guidelines recommend screening primarily for individuals with a strong family history of UIA/SAH or autosomal dominant polycystic kidney disease (ADPKD). However, these groups account for only a minority of patients with UIAs.

Smoking is a major modifiable risk factor for UIA formation and rupture. Preliminary studies suggest that UIA prevalence may be substantially higher among smokers than in the general population, but prospective data are limited, particularly in men.

This prospective screening study aims to determine the prevalence of UIAs in active and recent smokers aged 30-60 years with a smoking history of at least 10 pack-years. We hypothesize that UIA prevalence in this population is significantly higher than in the general population and may approach that of established high-risk groups.

Participants will undergo non-contrast 3T magnetic resonance angiography (time-of-flight sequence). Baseline demographic and clinical characteristics, smoking habits, nicotine dependence, and quality of life will be assessed using REDCap questionnaires. Imaging findings will be communicated to participants, and those with detected aneurysms or relevant incidental findings will be referred for standard clinical evaluation. At 30 (±14) days after MRI, smoking habits, nicotine dependence, quality of life, and consequences of screening will be reassessed. The study will also evaluate the clinical implications and costs of screening.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

Unruptured intracranial aneurysms (UIA) are an asymptomatic but potentially life-threatening cardiovascular condition. Rupture leads to aneurysmal subarachnoid hemorrhage (SAH), which is associated with high morbidity and mortality and causes 25% of all cerebrovascular-related deaths. In Switzerland, approximately 275'000 people harbor an UIA. Screening with imaging for detection of UIA to occlude them preventively and thus reduce SAH incidence is recommended according to current guidelines only in patients with ≥2 family members with a history of UIA/SAH or who suffer from autosomal dominant polycystic kidney disease (ADPKD). In these two groups, considered to be at high risk of having UIA, the prevalence of UIA is estimated to be 10%, compared with an approximate prevalence of 3.2% in the general population. However, patients with a positive family history for ≥2 family members or ADPKD represent an absolute minority of all UIA patients.

In contrast, smoking is common in SAH patients and is the most substantial risk factor for SAH. Approximately 40% of patients presenting with SAH are active smokers, and 39% of smokers with UIA will experience SAH during their lifetime. There are few but interesting data on the prevalence of UIA in middle-aged women who are smokers, as the incidence of SAH is highest in this subgroup. A retrospective nested case-control study in 30 to 60-year-old women who underwent head MRI for various indications found an UIA prevalence of 19% in female smokers compared to a prevalence of 1.9% in non-smoking females. Further, a recent small screening study found an UIA prevalence of 12% (5 out of 43) in female smokers.

Switzerland has implemented several tobacco control measures over the past 25 years, and tobacco use declined moderately until 2007. Since then, smoking prevalence has stabilized but remains relevantly high at approximately one-quarter of the population. 27% of the Swiss population (15 years and older) are active smokers, and 22% are former smokers. Smoking 20 or more cigarettes a day is considered heavy smoking, is prevalent in 6% of the population and is more common in men (8% men, 4% women). Although previous studies screened women exclusively, smoking is the most critical risk factor for SAH in both sexes, and Swiss men are more frequently heavy smokers than women.

Smoking cessation leads to a decrease in SAH incidence and is, contrary to ADPKD and positive family history of SAH/UIA, a risk factor that can be targeted with lifestyle modifications to prevent future SAH. These data and the continuing relevant health burden caused by smoking challenge the current screening approach towards a risk factor-based UIA screening strategy targeting smoking patients. To investigate the value of such risk factor-based screening, more extensive data on UIA prevalence in smokers is needed, particularly in men, because they are missing.

We hypothesize that the prevalence of UIA in active smokers is relevantly higher than the average UIA-prevalence of 3.2% and comparable to other high-risk groups (≥2 family members with a history of SAH/UIA, ADPKD) in whom guidelines currently recommend screening. Further, we hypothesize that in a relevant proportion of UIAs that could potentially be detected by such screening, the risk of natural history is higher than the risk of treatment resulting in a recommendation to perform preventive aneurysm occlusion or to undergo lifestyle modifications and follow-up with imaging.

After obtaining the signed informed consent and inclusion in the study, demographics, risk factors for SAH / UIA, QoL (15-D questionnaire), and nicotine dependence, will be assessed in an online questionnaire and with help of an online survey tool (REDCap). The 3T-MRI examination will be scheduled as a next step, and the appointment will be communicated to the participant. The 3T-MRI exams will take place at the Translational Imaging Senter in Sitem-insel. As MRI machine we will use a 3 T scanner (MAGNETOM Prisma, Siemens Healthcare) with a standard head coil. The time for acquiring the necessary TOF-angiography sequence is approximately 5 minutes. After the examination, participants can go directly home and no further examinations will be performed at this appointment. Within seven days after the examination, participants will be contacted by the study team via telephone and findings of the examination will be communicated. If a UIA or an incidental finding is detected, the patients will be called to a consultation in the outpatient clinic outside of the study and will be managed based on the finding with standard care. 30 (±14) days after the MRI examination, QoL, changes in smoking habits, and nicotine dependence will again be collected via an online questionnaire and with help of an online survey tool (REDCap). Furthermore, planned or completed interventions and consequences of the screening findings will be collected, as well as costs of screening and potential interventions will be recorded.

The maximum duration of the study after the MRI examination is 30 (±14) days. Depending on the availability of MRI slots, the period between inclusion and MRI examination may vary but should not exceed 8 (±4) weeks.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

200

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

    • Canton of Bern
      • Bern, Canton of Bern, Sveitsi, 3010
        • Rekrytointi
        • Inselspital Bern, Department of Neurosurgery
        • Ottaa yhteyttä:
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

30 vuotta - 60 vuotta (Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Women and men
  • Age 30-60 years
  • Active cigarette smoking with a cumulative exposure ≥ 10 pack-years
  • Smoking cessation no longer than 6 months ago (<6 months

Exclusion Criteria:

  • Contraindications to undergo MRI
  • Patients with known UIA
  • History of subarachnoid hemorrhage
  • History of polycystic kidney disease, Ehlers-Danlos syndrome, Marfan's syndrome, fibromuscular dysplasia, Moya-Moya disease, or Loeys-Dietz syndrome, history of ≥2 family members with SAH/UIA
  • Pregnancy

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Diagnostiikka
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: screening for unruptured intracranial aneurysms

3T-MRI examination for Unruptured intracranial aneurysms

After obtaining the signed informed consent, demographics, risk factors for SAH / UIA, QoL (15-D questionnaire), and nicotine dependence, will be assessed in an online questionnaire. The 3T-MRI examination will be performed. The time for acquiring the necessary TOF-angiography sequence is approximately 5 minutes. Within seven days after the examination, participants will be contacted by the study team via telephone and findings of the examination will be communicated. If a UIA or an incidental finding is detected, the patients will be called to a consultation in the outpatient clinic outside of the study and will be managed based on the finding with standard care. 30 (±14) days after the MRI examination, QoL, changes in smoking habits, and nicotine dependence will again be collected via an online questionnaire. Furthermore, planned or completed interinterventions and consequences of the screening findings will be collected.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
percentage of Unruptured intracranial aneurysms detected by screening
Aikaikkuna: 30 days after MRI

Diagnostic yield calculated as the percentage of UIAs detected by screening

30 days after MRI

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Kind of interventions for detected Unruptured intracranial aneurysms (none, observation/lifestyle modifications, preventive occlusion)
Aikaikkuna: 30 days after MRI

Interventions for detected Unruptured intracranial aneurysms (none, observation/lifestyle modifications, preventive occlusion)

30 days after MRI
Location of detected Unruptured intracranial aneurysms
Aikaikkuna: 7 days after MRI
7 days after MRI
Morphology of detected Unruptured intracranial aneurysms
Aikaikkuna: 7 days after MRI
7 days after MRI
Size of detected Unruptured intracranial aneurysms
Aikaikkuna: 7 days after MRI
7 days after MRI
Prevalence of incidental findings
Aikaikkuna: 7 days after MRI
7 days after MRI
Description of incidental MRI findings
Aikaikkuna: 7 days after Baseline MRI
7 days after Baseline MRI
Health Related Quality of Life (HRQoL) 15D
Aikaikkuna: at Baseline and 30 days after Baseline MRI

15D is a generic, comprehensive, 15-dimensional, standardized, self-administered measure of health-related quality of life (HRQoL). It includes the following 15 dimensions: breathing, mental function, speech (communication), vision, mobility, usual activities, vitality, hearing, eating, elimination, sleeping, distress, discomfort and symptoms, sexual activity, and depression. The maximum score is 1 (no problems on any dimension) and the minimum score is 0. A change of 0.02-0.03 has been observed to be such that people can feel the difference.

at Baseline and 30 days after Baseline MRI
Effect of smoking dependency/smoking habits
Aikaikkuna: assessed before and after MRI
assessed before and after MRI
Costs of screening
Aikaikkuna: day 7 after MRI

Costs of screening compared to costs of SAH

day 7 after MRI
Costs of potential interventions
Aikaikkuna: day 7 after MRI

Costs of potential interventions (including incidental findings) compared to costs of SAH

day 7 after MRI
UIA detection rate with software
Aikaikkuna: day 7 after MRI
day 7 after MRI
Prevalence ouf detected UIAs stratified by sex
Aikaikkuna: day 7 after MRI
day 7 after MRI
Prevalence ouf detected UIAs stratified by pack-years
Aikaikkuna: day 7 after MRI
day 7 after MRI
Prevalence ouf detected UIAs stratified by age
Aikaikkuna: day 7 after MRI
day 7 after MRI

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Päätutkija: Johannes Goldberg, MD, Inselspital Bern, Department of Neurosurgery

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 28. heinäkuuta 2023

Ensisijainen valmistuminen (Arvioitu)

Lauantai 31. heinäkuuta 2027

Opintojen valmistuminen (Arvioitu)

Maanantai 31. tammikuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 26. lokakuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 10. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 16. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 16. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 10. marraskuuta 2026

Viimeksi vahvistettu

Torstai 1. lokakuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • 2023-01023
  • 2023 (Yhdysvaltain NIH-apuraha/sopimus)

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .